News you can use
Myron Yaster MD
From Myron Yaster MD
Here is the weblink
https://pedsanesthesia.org/vote-now-spa-board-of-directors-2026-election/
“Are you an SPA faculty member passionate about shaping the next generation of pediatric anesthesiologists?
From Philip Carullo MD, Children’s Healthcare Atlanta, Emory School of Medicine and Rebecca Nause-Osthoff, MD, Clinical Associate Professor of Anesthesiology, Program Director, University of Michigan
SPAERS (SPA’s Engagement with Residents and Students) is expanding its committee structure and looking for dedicated faculty to help drive resident and student engagement at the national level. Whether your interest lies in mentorship, pipeline development, or advocacy for trainees, there’s a place for you here.
Join us for a general interest meeting to learn about our newest initiatives and how you can get involved. We’d love to have you on the team.
Session 1: Tuesday, July 21, 2026, 8:00 PM EST
https://us06web.zoom.us/j/82822753041
Session 2: Monday, August 17, 2026, 8:00 PM EST
https://us06web.zoom.us/j/87233019959
Sign up for a time that works for you. We’d love to have you on the team.”
From Nancy Finnel
Octapharma USA Announces Expanded FDA Approval of wilate® for von Willebrand Disease Prophylaxis in Children Younger Than 6 Years
On July 2, 2026, the U.S. Food and Drug Administration (FDA) approved the use of wilate® (von Willebrand Factor/Coagulation Factor VIII Complex [Human]) for routine prophylaxis to reduce the frequency of bleeding episodes in pediatric patients with von Willebrand Disease (VWD) who are younger than 6 years of age. This approval expands access to the first von Willebrand Factor (VWF) concentrate indicated for prophylactic treatment across all ages and forms of VWD, the most common inherited bleeding disorder
from AI NEJM OpenEvidence
Wilate is a human plasma-derived von Willebrand factor (VWF)/coagulation factor VIII (FVIII) complex indicated for the treatment of spontaneous and trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD), as well as in patients with mild or moderate VWD in whom desmopressin is known or suspected to be ineffective or contraindicated.
Mechanism of Action
VWF serves two key functions: (1) it mediates platelet adhesion to damaged sub-endothelium (providing primary hemostasis with immediate effect), and (2) it acts as a carrier protein that stabilizes endogenous FVIII, preventing its rapid degradation (a slightly delayed effect). Because Wilate also contains FVIII, it rapidly restores FVIII activity levels in addition to correcting VWF deficiency
